Where to spend the money ??
Post# of 148187
(Total Views: 527)
Posted On: 01/20/2020 12:31:47 PM
I hope NP finalizes the financing deal and this money will be very wisely used .
The priorities for where to spend the monies are clear (no surprises but needs to be done):
1) We need to launch the pivotal trial on Monotheraphy. The results already obtained are excellent and we need to cross the line and launch Leronlimab as Mono. The funds should be there to start as soon as possible (pending FDA green-light) with this. Once in the market we will start getting a much-needed revenue.
2) We need to further trials in NASH . Already Cencriviroc (Takeda a dual CCR2-CCR5 inhibitor) and Tropifexor (FXR agonist Novartis+Pfizer) are being evaluated in phase III. Maraviroc ( (Pfizer) CCR5, small molecule antagonist) also was successful in a murine model. However, Leronlimab seems to be vastly superior to all of these. The idea here is that the further we advance the results the more superior Lero will be and the higher the price anybody will have to pay for it. The approach that Pfizer is taking is to go for a combination approach https://seekingalpha.com/article/4215823-pfiz...n-approach What Lero has done ALONE is amazing but we need to explore partnerships once it is determine it is good on its own.
3) We need to further our Oncology indications. mTNBC is certainly a good start but the field out there is large and unexplored. Having a superior CCR5 antagonist really opens a large amount of doors. Maraviroc and Vicrivoc are already being tested with Keytruda (pembrolizumab), one of top-selling drugs ($7.1B) !!! The more effective and less secondary effects of Lero would beat hands-down these small molecule agonists (by the way, Pembrolizumab is also a humanized antibody).
We need to start trying Lero with Keytruda or with Opdivo or Yervoy or others, in different indications. This will give us the piggy-tail we need to enter the stage with a big bang !!!; we are talking BP pharma here, and maybe (therapeutically-speaking) they will be piggy-tailing on us, not the other way around.
So, we need funds to continue progressing and making our Lero more valuable. Also, we need to increase the speed of our research . Sometimes it is not who is better, but, who gets there first. Let’s secure the funding and accelerate the human or otherwise trials to show the real worth of Leronlimab (clinically and economically.)
The priorities for where to spend the monies are clear (no surprises but needs to be done):
1) We need to launch the pivotal trial on Monotheraphy. The results already obtained are excellent and we need to cross the line and launch Leronlimab as Mono. The funds should be there to start as soon as possible (pending FDA green-light) with this. Once in the market we will start getting a much-needed revenue.
2) We need to further trials in NASH . Already Cencriviroc (Takeda a dual CCR2-CCR5 inhibitor) and Tropifexor (FXR agonist Novartis+Pfizer) are being evaluated in phase III. Maraviroc ( (Pfizer) CCR5, small molecule antagonist) also was successful in a murine model. However, Leronlimab seems to be vastly superior to all of these. The idea here is that the further we advance the results the more superior Lero will be and the higher the price anybody will have to pay for it. The approach that Pfizer is taking is to go for a combination approach https://seekingalpha.com/article/4215823-pfiz...n-approach What Lero has done ALONE is amazing but we need to explore partnerships once it is determine it is good on its own.
3) We need to further our Oncology indications. mTNBC is certainly a good start but the field out there is large and unexplored. Having a superior CCR5 antagonist really opens a large amount of doors. Maraviroc and Vicrivoc are already being tested with Keytruda (pembrolizumab), one of top-selling drugs ($7.1B) !!! The more effective and less secondary effects of Lero would beat hands-down these small molecule agonists (by the way, Pembrolizumab is also a humanized antibody).
We need to start trying Lero with Keytruda or with Opdivo or Yervoy or others, in different indications. This will give us the piggy-tail we need to enter the stage with a big bang !!!; we are talking BP pharma here, and maybe (therapeutically-speaking) they will be piggy-tailing on us, not the other way around.
So, we need funds to continue progressing and making our Lero more valuable. Also, we need to increase the speed of our research . Sometimes it is not who is better, but, who gets there first. Let’s secure the funding and accelerate the human or otherwise trials to show the real worth of Leronlimab (clinically and economically.)
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼